MCM
AZN icon

Mitchell Capital Management’s AstraZeneca AZN Stock Holding History

Mitchell Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,689
Closed -$1.17M – 118
2023
Q4 		$1.17M Sell
8,689
-357
-4% -$46.4K 0.25% 85
2023
Q3 		$1.23M Sell
9,046
-61
-0.7% -$8.33K 0.29% 81
2023
Q2 		$1.3M Buy
9,107
+426
+5% +$62.7K 0.3% 83
2023
Q1 		$1.21M Buy
8,681
+34
+0.4% +$4.57K 0.3% 87
2022
Q4 		$1.17M Buy
8,647
+20
+0.2% +$2.51K 0.32% 89
2022
Q3 		$946K Sell
8,627
-253
-3% -$32.1K 0.27% 94
2022
Q2 		$1.17M Buy
8,880
+97
+1% +$12.7K 0.33% 83
2022
Q1 		$1.17M Buy
8,783
+483
+6% +$57.9K 0.26% 95
2021
Q4 		$967K Buy
8,300
+48
+0.6% +$5.65K 0.2% 105
2021
Q3 		$991K Buy
8,252
+131
+2% +$15.2K 0.22% 111
2021
Q2 		$973K Buy
8,121
+618
+8% +$67.8K 0.21% 116
2021
Q1 		$746K Buy
7,503
+1,384
+23% +$139K 0.18% 123
2020
Q4 		$612K Sell
6,119
-5,034
-45% -$533K 0.15% 119
2020
Q3 		$1.22M Sell
11,153
-113
-1% -$12.6K 0.35% 82
2020
Q2 		$1.19M Sell
11,266
-1,106
-9% -$114K 0.38% 79
2020
Q1 		$1.1M Buy
12,372
+1,209
+11% +$114K 0.43% 74
2019
Q4 		$1.11M Sell
11,163
-160
-1% -$15.1K 0.35% 77
2019
Q3 		$1.01M Buy
11,323
+1,576
+16% +$137K 0.34% 83
2019
Q2 		$805K Buy
9,747
+160
+2% +$12.5K 0.27% 88
2019
Q1 		$775K Sell
9,587
-589
-6% -$46.4K 0.27% 84
2018
Q4 		$773K Sell
10,176
-12
-0.1% -$937 0.33% 70
2018
Q3 		$806K Buy
10,188
+1,677
+20% +$127K 0.26% 74
2018
Q2 		$598K Buy
8,511
+1,959
+30% +$141K 0.22% 75
2018
Q1 		$458K Buy
6,552
+2,552
+64% +$177K 0.17% 76
2017
Q4 		$278K Buy
4,000
+890
+29% +$60K 0.1% 77
2017
Q3 		$211K Buy
+3,110
New +$196K 0.08% 63

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Mitchell Capital Management's AZN Position: Q1 2024 in Review

Mitchell Capital Management sold out of AstraZeneca (AZN) in Q1 2024, closing a stake of 8,689 shares — an estimated $1.17M sold.

Mitchell Capital Management first reported a position in AZN in Q3 2017 and held it in 26 quarters. The position peaked at $1.3M in Q2 2023. 1,142 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

  • Mitchell Capital Management reported no remaining AstraZeneca position as of Q1 2024 after selling out during the quarter.
  • Mitchell Capital Management sold 8,689 AstraZeneca shares in Q1 2024, an estimated $1.17M.
  • Mitchell Capital Management first reported a position in AstraZeneca in Q3 2017 and held it in 26 quarters.
  • Mitchell Capital Management's AstraZeneca position peaked at $1.3M in Q2 2023.
  • 1,142 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on Mitchell Capital Management's 13F filing for Q1 2024, filed 6 May 2024.